A detailed history of State Street Corp transactions in Erasca, Inc. stock. As of the latest transaction made, State Street Corp holds 6,027,620 shares of ERAS stock, worth $16.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,027,620
Previous 2,458,180 145.21%
Holding current value
$16.9 Million
Previous $5.8 Million 183.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.17 - $3.28 $7.75 Million - $11.7 Million
3,569,440 Added 145.21%
6,027,620 $16.5 Million
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.63 $1.41 Million - $2.07 Million
787,495 Added 47.14%
2,458,180 $5.8 Million
Q1 2024

May 15, 2024

BUY
$1.67 - $2.55 $8,986 - $13,721
5,381 Added 0.32%
1,670,685 $3.44 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.49 $284,299 - $423,895
170,239 Added 11.39%
1,665,304 $3.55 Million
Q3 2023

Nov 14, 2023

BUY
$1.97 - $2.91 $10,208 - $15,079
5,182 Added 0.35%
1,495,065 $2.95 Million
Q2 2023

Aug 14, 2023

BUY
$2.57 - $3.3 $567,229 - $728,349
220,712 Added 17.39%
1,489,883 $4.11 Million
Q1 2023

May 15, 2023

SELL
$2.74 - $4.44 $7.18 Million - $11.6 Million
-2,621,376 Reduced 67.38%
1,269,171 $3.82 Million
Q4 2022

Feb 14, 2023

BUY
$3.89 - $8.57 $7.15 Million - $15.8 Million
1,837,982 Added 89.55%
3,890,547 $16.8 Million
Q3 2022

Nov 15, 2022

BUY
$5.82 - $10.68 $6.34 Million - $11.6 Million
1,090,085 Added 113.26%
2,052,565 $16 Million
Q2 2022

Aug 15, 2022

BUY
$4.58 - $8.72 $289,506 - $551,199
63,211 Added 7.03%
962,480 $5.36 Million
Q1 2022

May 16, 2022

BUY
$8.6 - $15.48 $4.58 Million - $8.25 Million
532,888 Added 145.45%
899,269 $7.73 Million
Q4 2021

Feb 14, 2022

BUY
$12.51 - $22.75 $1.34 Million - $2.44 Million
107,097 Added 41.3%
366,381 $5.71 Million
Q3 2021

Nov 15, 2021

BUY
$17.43 - $24.34 $4.52 Million - $6.31 Million
259,284 New
259,284 $5.5 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $343M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.